keyword
MENU ▼
Read by QxMD icon Read
search

prophylaxis pneumocystis

keyword
https://www.readbyqxmd.com/read/29896781/an-outbreak-of-pneumocytis-jirovecii-pneumonia-among-liver-transplant-recipients
#1
Romain Miguel Montanes, Laure Elkrief, David Hajage, Pauline Houssel, Bruno Fantin, Claire Francoz, Didier Dreyfuss, Jean-Damien Ricard, François Durand
BACKGROUND: An outbreak of Pneumocystis pneumonia (PCP) in liver transplant recipients occurred between 2009 and 2011 at the Beaujon University Hospital just after immediate release tacrolimus was replaced by extended release tacrolimus. We conducted a retrospective study to analyse the transmission mode of Pneumocystis, the role of the change in the immunosuppressive regimen and the factors associated with PCP. PATIENTS AND METHODS: To analyse transmission, we built a transmission map...
June 13, 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29890253/prophylaxis-and-treatment-of-pneumocystis-jirovecii-pneumonia-after-solid-organ-transplantation
#2
REVIEW
Susanne Brakemeier, Anja Pfau, Bianca Zukunft, Klemens Budde, Peter Nickel
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic infection diagnosed in immunocompromized patients. After solid organ transplantation, early infection has decreased as a result of effective prophylaxis, but late infections and even outbreaks caused by interpatient transmission of pneumocystis by air are present in the SOT community. Different risk factors for PJP have been described and several indications for PJP prophylaxis have to be considered by clinicians in patients even years after transplantation...
June 8, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29866879/pentamidine-for-prophylaxis-against-pneumocystis-jirovecii-pneumonia-in-pediatric-oncology-patients-receiving-immunosuppressive-chemotherapy
#3
Melissa Quinn, J T Fannin, Joseph Sciasci, Allison Bragg, Patrick K Campbell, Delia Carias, Kristine R Crews, David Gregornik, Sima Jeha, Gabriela Maron, Jennifer L Pauley, Hope D Swanson, Joshua Wolf, William Greene
BACKGROUND: Pneumocystis jirovecii pneumonia is a life-threatening opportunistic infection in children receiving immunosuppressive chemotherapy. Without prophylaxis, up to 25% of pediatric oncology patients receiving chemotherapy will develop Pneumocystis jirovecii pneumonia. Trimethoprim-sulfamethoxazole is the preferred agent for prophylaxis against Pneumocystis jirovecii pneumonia. Pentamidine may be an acceptable alternative for pediatric patients unable to tolerate trimethoprim-sulfamethoxazole...
June 4, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29844519/pneumocystis-jirovecii-pneumonia-in-hiv-uninfected-rituximab-treated-non-hodgkin-lymphoma-patients
#4
Kai-Che Wei, Chenglen Sy, Shang-Yin Wu, Tzu-Jung Chuang, Wei-Chun Huang, Ping-Chin Lai
Rituximab is associated with a higher incidence of Pneumocystis jirovecii pneumonia infection. Pneumocystis prophylaxis is advised in many immunocompromised populations treated with rituximab. However, the beneficial effect of pneumocystis prophylaxis in HIV-uninfected, rituximab-treated non-Hodgkin lymphoma (NHL) patients has not been assessed. Thus, we conducted this retrospective study to explore pneumocystis infection in HIV-uninfected NHL patients who received at least three courses of chemotherapy without haematopoietic stem cell transplantation using the Taiwan National Health Insurance Research Database...
May 29, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29808456/late-onset-pneumocystis-jirovecii-pneumonia-pjp-in-patients-with-anca-associated-vasculitis
#5
El Hakem Matraiah, Nkiruka Olisaka, Mariana Philipos, David Walbaum, Paula Dospinescu, Nicholas Fluck, Neil Basu, Dana Kidder
Immunosuppression in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by increasing risk of infections including opportunistic infections like Pneumocystis jirovecii pneumonia (PJP). Available evidence on risk factors and indications for prophylaxis in AAV is derived from PJP occurring early in the course of AAV. In this retrospective study, we characterized the profile of PJP in patients with AAV. PJP cases were identified retrospectively based on positive polymerase chain reaction test from electronic record followed by confirmation from medical records over a 10-year period...
May 28, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29800121/increased-risk-of-infectious-complications-in-older-patients-with-indolent-non-hodgkin-lymphoma-exposed-to-bendamustine
#6
Monica Fung, Eric Jacobsen, Arnold Freedman, Daniel Prestes, Dimitrios Farmakiotis, Xiangmei Gu, Paul L Nguyen, Sophia Koo
Background: Bendamustine is a potent chemotherapy agent increasingly used to treat indolent non-Hodgkin lymphoma (iNHL). While effective, it causes significant T-cell lymphopenia, which may increase risk of infection. We examined infectious complications associated with bendamustine-containing regimens among older patients with iNHL. Methods: For this SEER-Medicare cohort study, we identified 9,395 patients with iNHL (follicular, marginal zone, Waldenström's macroglobulinemia) treated with chemotherapy from 2006-2013...
May 25, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29668131/-severe-hypoxemic-respiratory-failure-caused-by-pneumocystis-jirovecii-in-a-late-kidney-transplant-recipient
#7
John Fredy Nieto-Ríos, Mónica Zuluaga-Quintero, Arbey Aristizábal-Alzate, Catalina Ocampo-Kohn, Lina María Serna-Higuita, Isabel Cristina Ramírez-Sánchez, Gustavo Adolfo Zuluaga-Valencia
Pneumonia caused by Pneumocystis jirovecii is an uncommon infection in kidney transplant patients that can have an acute and rapid progression to respiratory failure and death. The period of greatest risk occurs in the first six months after the transplant, and it relates to the high doses of immunosuppression drugs required by patients. However, it may occur late, associated with the suspension of prophylaxis with trimethoprim-sulfamethoxazole.We present two cases of renal transplant patients who had severe hypoxemic respiratory failure due to P...
March 15, 2018: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/29652202/effect-of-sulfasalazine-use-on-the-presence-of-pneumocystis-organisms-in-the-lung-among-patients-with-rheumatoid-arthritis-a-test-negative-design-case-control-study-with-pcr-tests
#8
Takahiro Nunokawa, Naoto Yokogawa, Kota Shimada, Shoji Sugii
OBJECTIVE: To evaluate the effect of sulfasalazine (SSZ) on the presence of Pneumocystis jirovecii (P. jirovecii) in the lungs of rheumatoid arthritis (RA) patients. METHODS: We retrospectively studied episodes of suspected P. jirovecii pneumonia (PJP) which were examined for P. jirovecii with polymerase chain reaction (PCR). We employed a test negative design case-control study; the cases were episodes of suspected PJP that were positive for PCR, and the controls were episodes of suspected PJP that were negative for PCR...
May 3, 2018: Modern Rheumatology
https://www.readbyqxmd.com/read/29610164/-pneumocystis-jirovecii-pneumonia-during-sirolimus-therapy-for-kaposiform-hemangioendothelioma
#9
Thomas B Russell, Emily K Rinker, Claire S Dillingham, Laurence B Givner, Thomas W McLean
Sirolimus is an effective therapy for children with kaposiform hemangioendothelioma with or without the Kasabach-Merritt phenomenon. We report the case of a child with kaposiform hemangioendothelioma and the Kasabach-Merritt phenomenon who developed Pneumocystis carinii pneumonia (PCP) while on sirolimus and a prednisolone taper, after lack of adequate response to prednisolone, propranolol, and vincristine. He had a prompt positive clinical and laboratory response to sirolimus, but 4 weeks after starting it, at the age of 4 months, he developed PCP...
April 2018: Pediatrics
https://www.readbyqxmd.com/read/29572070/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-agents-targeting-lymphoid-or-myeloid-cells-surface-antigens-ii-cd22-cd30-cd33-cd38-cd40-slamf
#10
REVIEW
L Drgona, C Gudiol, S Lanini, B Salzberger, G Ippolito, M Mikulska
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4 and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family...
June 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29555315/increased-incidence-of-nocardial-infections-in-an-era-of-atovaquone-prophylaxis-in-allogeneic-hematopoietic-stem-cell-transplant-recipients
#11
Alfonso Molina, Drew J Winston, Darren Pan, Gary J Schiller
Nocardial infections have been rare after allogeneic hematopoietic stem cell transplantation (HSCT). We report 10 recent cases of late-onset nocardiosis (median time of onset of 508 days after transplantation) primarily in patients on high doses of corticosteroids for graft-versus-host disease. All 10 patients had pulmonary infection caused by Nocardia species susceptible to trimethoprim-sulfamethoxazole (TMP-SMX). At time of diagnosis 8 of 10 patients were not receiving TMP-SMX for prophylaxis of Pneumocystis jiroveci pneumonia (PJP; 7 on atovaquone, 1 on i...
March 16, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29534652/the-impact-of-absolute-cd4-count-and-percentage-discordance-on-pneumocystis-jirovecii-pneumonia-prophylaxis-in-hiv-infected-patients
#12
Henry Anyimadu, Chandra Pingili, Vel Sivapalan, Yael Hirsch-Moverman, Sharon Mannheimer
Current guidelines suggest that HIV-infected patients should receive chemoprophylaxis against Pneumocystis jirovecii pneumonia (PJP) if they have a cluster determinant 4 (CD4) count <200 cells/mm3 or oropharyngeal candidiasis. Persons with CD4 percentage (CD4%) below 14% should also be considered for prophylaxis. Discordance between CD4 count and CD4% occurs in 16% to 25% of HIV-infected patients. Provider compliance with current PJP prophylaxis guidelines when such discordance is present was assessed. Electronic medical records of 429 HIV-infected individuals who had CD4 count and CD4% measured at our clinic were reviewed...
January 2018: Journal of the International Association of Providers of AIDS Care
https://www.readbyqxmd.com/read/29533748/guidelines-for-prophylaxis-of-pneumocystis-pneumonia-cannot-rely-solely-on-cd4-cell-count-in-autoimmune-and-inflammatory-diseases
#13
Gildas Baulier, Nahema Issa, Frederic Gabriel, Isabelle Accoceberry, Fabrice Camou, Pierre Duffau
OBJECTIVES: Guidelines for preventing Pneumocystis pneumonia (PCP) in HIV patients are based on CD4 below 200/mm3. Such cut-off value is suggested to guide prophylaxis in non-HIV conditions (NHIV) especially in autoimmune and inflammatory diseases (AD). We aimed to determine if CD4 could be used to guide PCP prophylaxis in AD. METHODS: CD4 and lymphocyte-count were retrospectively studied in patients diagnosed with PCP between January 2013 and February 2016. RESULTS: 129 patients were included...
May 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29514393/single-center-outbreak-of-pneumocystis-jirovecii-pneumonia-in-heart-transplant-recipients
#14
Giacomo Veronese, Enrico Ammirati, Maria Cristina Moioli, Rossella Baldan, Carlo Andrea Orcese, Gisele De Rezende, Silvio Veronese, Gabriella Masciocco, Enrico Perna, Giovanna Travi, Massimo Puoti, Manlio Cipriani, Simon Tiberi, Daniela Cirillo, Maria Frigerio
BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) outbreaks are described in solid organ transplant recipients. Few reports suggest interhuman transmission with important infection control implications. We described a large PJP outbreak in heart transplant (HTx) recipients. METHODS: Six cases of PJP occurred in HTx recipients within 10 months in our hospital. Demographics, clinical characteristics, treatment and outcomes were described. To identify contacts among individuals a review of all dates of out-patient visits and patient hospitalizations was performed...
June 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29514232/managing-advanced-hiv-disease-in-a-public-health-approach
#15
Nathan Ford, Graeme Meintjes, Alexandra Calmy, Helen Bygrave, Chantal Migone, Marco Vitoria, Martina Penazzato, Lara Vojnov, Meg Doherty
In 2017, the World Health Organization (WHO) published guidelines for the management of advanced human immunodeficiency virus (HIV) disease within a public health approach. Recent data suggest that more than a third of people starting antiretroviral therapy (ART) do so with advanced HIV disease, and an increasing number of patients re-present to care at an advanced stage of HIV disease following a period of disengagement from care. These guidelines recommend a standardized package of care for adults, adolescents, and children, based on the leading causes of morbidity and mortality: tuberculosis, severe bacterial infections, cryptococcal meningitis, toxoplasmosis, and Pneumocystis jirovecii pneumonia...
March 4, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29512868/lymphopenia-is-associated-with-late-onset-pneumocystis-jirovecii-pneumonia-in-solid-organ-transplantation
#16
W A Werbel, M G Ison, M P Angarone, A Yang, V Stosor
BACKGROUND: Pneumocystis jirovecii pneumonia (PJP) affected 5%-15% of solid organ transplant (SOT) recipients prior to universal prophylaxis, classically with trimethoprim-sulfamethoxazole (TMP-SMX). Guidelines generally recommend 6-12 months of prophylaxis post-SOT, yet optimal duration and robust PJP risk stratification have not been established. METHODS: A retrospective, single-center, case-control study of PJP among SOT recipients from January 1998 to December 2013 was conducted...
June 2018: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/29507493/procarbazine-lomustine-and-vincristine-toxicity-in-low-grade-gliomas
#17
G Jutras, K Bélanger, N Letarte, J-P Adam, D Roberge, B Lemieux, É Lemieux-Blanchard, L Masucci, C Ménard, J P Bahary, R Moumdjian, F Berthelet, M Florescu
Background: Procarbazine, lomustine, and vincristine (pcv) significantly improve survival outcomes in lgg (low-grade gliomas). Administration of pcv to lgg patients increased tremendously over the past years as it went from 2 patients per year between 2005 and 2012 to 23 patients in 2015 only in our centre. However, serious hematological and non-hematological adverse events may occur. The purpose of this study was to evaluate the toxicity of pcv and its clinical relevance in our practice...
February 2018: Current Oncology
https://www.readbyqxmd.com/read/29488599/-pneumocystis-jiroveci-pneumonia-following-infliximab-therapy-in-patient-with-crohn-s-disease
#18
Daniela Fluxá, Jorge Segovia, Matías Florenzano, Jessica Salinas, Lilian Flores, Daniela Simian, Rodrigo Quera
There are no evidence-based guidelines about prophylaxis against Pneumocystis jiroveci pneumonia in inflammatory bowel disease. We report a case of P. jiroveci pneumonia in patient with Crohn's disease receiving infliximab and methotrexate. This case emphasizes the importance of considering the possibility of this infection in inflammatory bowel disease patients treated on biological therapy.
October 2017: Revista Chilena de Infectología: órgano Oficial de la Sociedad Chilena de Infectología
https://www.readbyqxmd.com/read/29459143/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-soluble-immune-effector-molecules-i-anti-tumor-necrosis-factor-%C3%AE-agents
#19
REVIEW
J W Baddley, F Cantini, D Goletti, J J Gómez-Reino, E Mylonakis, R San-Juan, M Fernández-Ruiz, J Torre-Cisneros
BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting tumour necrosis factor-α (TNF-α) and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family...
February 6, 2018: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/29454849/escmid-study-group-for-infections-in-compromised-hosts-esgich-consensus-document-on-the-safety-of-targeted-and-biological-therapies-an-infectious-diseases-perspective-intracellular-signaling-pathways-tyrosine-kinase-and-mtor-inhibitors
#20
REVIEW
M Reinwald, J T Silva, N J Mueller, J Fortún, C Garzoni, J W de Fijter, M Fernández-Ruiz, P Grossi, J M Aguado
BACKGROUND: The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biologic therapies. AIMS: To review, from an infectious diseases perspective, the safety profile of therapies targeting different intracellular signaling pathways and to suggest preventive recommendations. SOURCES: Computer-based Medline searches with MeSH terms pertaining to each agent or therapeutic family...
February 16, 2018: Clinical Microbiology and Infection
keyword
keyword
73474
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"